Antifungal Susceptibility Profile of Candida Albicans Isolated from Vulvovaginal Candidiasis in Xinjiang Province of China
- 59 Downloads
We investigated the antifungal susceptibility profiles of 207 independent Candida albicans strains isolated from patients with vulvovaginal candidiasis (VVC) in Xinjiang Province of China. Using CLSI M27-A3 and M27-S4 guidelines, anidulafungin and micafungin were the most active drugs against C. albicans showing an MIC50/MIC90 corresponding to 0.016/0.0313 µg/mL, followed by caspofungin (0.25/0.25 µg/mL), posaconazole (0.125/0.5 µg/mL), ravuconazole (0.063/1 µg/mL), itraconazole (0.125/1 µg/mL), amphotericine B (0.5/1 µg/mL), isavuconazole (0.063/2 µg/mL), 5-flucytosine (1/2 µg/mL), voriconazole (0.125/4 µg/mL), and fluconazole (0.5/4 µg/mL). 96.1% (199)–100.0% (207) isolates were sensitive to the three echinocandins tested, amphotericine B and 5-flucytosine. The in vitro activity of triazoles against all isolates tested was variable; itraconazole and voriconazole had reduced the activity to almost half of the isolates (55.1% (114) and 51.2% (106) susceptible, respectively). Fluconazole was active against 76.3% (158) isolates tested. The new triazoles ravuconazole, isavuconazole and posaconazole showed good in vitro potency against 89.9% (186)–95.2% (197) of isolates with the geometric mean MIC (µg/mL) of 0.10, 0.12 and 0.14 µg/mL, respectively. In conclusion, our study indicates that for effective management of systemic candidiasis in Xinjiang Province of China, it is important to determine the susceptibility profiles of isolated C. albicans from patients with VVC.
KeywordsAntifungal susceptibility Candida albicans Vulvovaginal candidiasis Xinjiang Province
This study was supported by Suzhou New & Hi-Tech IDZ grant 2017Z008, in part by Shanghai Science Foundation of China under Grant 16DZ0500401. Seyedmojtaba Seyedmousavi is presently supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Compliance with Ethical Standards
Conflict of interest
All authors declare that they have no conflict of interest.
- 8.De Pádua RF, Guilhermetti E, Svidzinski TE. In vitro activity of antifungal agents on yeasts isolated from vaginal secretion. Acta Scientiarum. 2003;25:51–4.Google Scholar
- 11.Brandolt TM, Klafke GB, Gonçalves CV, Bitencourt LR, Martinez AMBd, Mendes JF, et al. Prevalence of Candida spp. in cervical-vaginal samples and the in vitro susceptibility of isolates. Braz. J Microbiol. 2017;48:145–50.Google Scholar
- 13.Dota KFD, Consolaro MEL, Svidzinski TIE, Bruschi ML. Antifungal activity of Brazilian propolis microparticles against yeasts isolated from vulvovaginal candidiasis. Evid-Based Complement Altern. 2011;2011:201953.Google Scholar
- 16.Asticcioli S, Sacco L, Daturi R, Matti C, Nucleo E, Zara F, et al. Trends in frequency and in vitro antifungal susceptibility patterns of Candida isolates from women attending the STD outpatients clinic of a tertiary care hospital in Northern Italy during the years 2002-2007. New Microbiol. 2009;32:199–204.PubMedGoogle Scholar
- 17.Dias LB. Melhem MdSC, Szeszs MW, Meirelles Filho J, Hahn RC. Vulvovaginal candidiasis in Mato Grosso, Brazil: pregnancy status, causative species and drugs tests. Braz. J Microbiol. 2011;42:1300–7.Google Scholar
- 23.Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods 2010 to 2012. J Clin Microbiol. 2010;2012(50):2846–56.Google Scholar
- 25.Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 3rd edition; Document M27-A3. 2008.Google Scholar
- 26.Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: 4th Informational Supplement-CLSI Document M27-S4-Wayne, PA. 2012.Google Scholar
- 33.Lin XY, Wang SL, Duan XL, Lan CG, Chen XJ, Xue J, et al. Review of clinical experience in itraconazole therapy for 10 years in China. J Clin Dermatol. 2003;32:429–30 (in Chinese).Google Scholar
- 36.Castanheira M, Messer SA, Rhomberg PR, Dietrich RR, Jones RN, Pfaller MA. Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia. 2014;178:1–9.CrossRefGoogle Scholar
- 37.Pfaller M, Diekema D, Messer S, Boyken L, Huynh H, Hollis R. Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole. J Clin Microbiol. 2002;40:1694–7.CrossRefGoogle Scholar
- 40.Pfaller M, Diekema D, Jones R, Sader HS, Fluit A, Hollis R, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol. 2001;39:3254–9.CrossRefGoogle Scholar
- 41.Pfaller M, Messer S, Boyken L, Rice C, Tendolkar S, Hollis R, et al. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J Clin Microbiol. 2004;42:3137–41.CrossRefGoogle Scholar
- 43.Guinea J, Peláez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008;52:1396–400.CrossRefGoogle Scholar
- 45.Pfaller M, Messer S, Boyken L, Hollis R, Rice C, Tendolkar S, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis. 2004;48:201–5.CrossRefGoogle Scholar